title: Aspirin in patients with coronary artery disease: is it simply irresistible?
authors.affiliation: Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Schapiro Research Building, R202 Baltimore, Maryland 21215, USA.
authors.forename: G V
authors.initials: GV
authors.lastname: Nair
authors.forename: C J
authors.initials: CJ
authors.lastname: Davis
authors.forename: M E
authors.initials: ME
authors.lastname: McKenzie
authors.forename: D R
authors.initials: DR
authors.lastname: Lowry
authors.forename: V L
authors.initials: VL
authors.lastname: Serebruany
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001550:Benzamidines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D003327:Coronary Disease / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D048909:Diabetes Complications; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010091:Oximes / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000517:prevention & control; D013927:Thrombosis / Q000517:prevention & control; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D001550:Benzamidines; D016861:Cyclooxygenase Inhibitors; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010091:Oximes; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014665:Vasodilator Agents; D004176:Dipyridamole; D000077144:Clopidogrel; D013930:Thromboxane-A Synthase; D013988:Ticlopidine; C091295:xemilofiban; D001241:Aspirin; D000077284:Abciximab; C100917:sibrafiban